AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orenstein, W. A.
Right arrow Articles by Cochi, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orenstein, W. A.
Right arrow Articles by Cochi, S. L.
Related Collections
Right arrow Immunization/Vaccines
Right arrow Other Infections
Right arrow Other Child and Adolescent Health

American Journal of Public Health, Vol 90, Issue 10 1521-1525, Copyright © 2000 by American Public Health Association

JOURNAL ARTICLE

Measles eradication: is it in our future?

WA Orenstein, PM Strebel, M Papania, RW Sutter, WJ Bellini and SL Cochi
National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Ga. 30333, USA.

Measles eradication would avert the current annual 1 million deaths and save the $1.5 billion in treatment and prevention costs due to measles in perpetuity. The authors evaluate the biological feasibility of eradicating measles according to 4 criteria: (1) the role of humans in maintaining transmission, (2) the availability of accurate diagnostic tests, (3) the existence of effective vaccines, and (4) the need to demonstrate elimination of measles from a large geographic area. Recent successes in interrupting measles transmission in the United States, most other countries in the Western Hemisphere, and selected countries in other regions provide evidence for the feasibility of global eradication. Potential impediments to eradication include (1) lack of political will in some industrialized countries, (2) transmission among adults, (3) increasing urbanization and population density, (4) the HIV epidemic, (5) waning immunity and the possibility of transmission from subclinical cases, and (6) risk of unsafe injections. Despite these challenges, a compelling case can be made in favor of measles eradication, and the authors believe that it is in our future. The question is when.


This article has been cited by other articles:


Home page
 Nurs EthicsHome page
J. Wood-Harper
Informing Education Policy on MMR: balancing individual freedoms and collective responsibilities for the promotion of public health
Nursing Ethics, January 1, 2005; 12(1): 43 - 58.
[Abstract] [PDF]

Home page
 PediatricsHome page
H. C. Meissner, P. M. Strebel, and W. A. Orenstein
Measles Vaccines and the Potential for Worldwide Eradication of Measles
Pediatrics, October 1, 2004; 114(4): 1065 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
M. Colomar, I. Puga, M. Lopez, M. Massot, J. I. Jorquera, M. Reina, S. Vilaro, and E. Espel
Neutralization of Measles Virus Infectivity and Antibody-Dependent Cell-Mediated Cytotoxicity Activity against an Epstein-Barr Virus-Infected Cell Line by Intravenous Administration of Immunoglobulin G
Clin. Vaccine Immunol., September 1, 2003; 10(5): 751 - 756.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Public Health Association